Status:

UNKNOWN

BMI-Associated Labor Induction: A Prospective Trial

Lead Sponsor:

Baystate Medical Center

Conditions:

Labor Induction

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

The primary objective of this study is to determine if planned induction of labor at 39 weeks for nulliparous with pre-pregnancy BMI ≥ 35 kg/m2 reduces the incidence of cesarean section compared to ex...

Detailed Description

Obesity in the obstetric population has reached epidemic proportions, affecting over 30% of reproductive-aged women in the United States (1). The increase in this morbidity is associated with large in...

Eligibility Criteria

Inclusion

  • Age 18 years and older
  • Pregnant, singleton gestation, vertex presentation
  • Nulliparous (no prior pregnancy delivered past 20 weeks)
  • Pre-pregnancy (self-reported in record of in EMR within 3 months of LMP) or 1st trimester (up to and including 14 weeks 0 days) BMI ≥ 35 kg/m2
  • Gestational age at enrollment 38 weeks 0 days and 38 weeks 6 days with dating confirmed by LMP and ultrasound performed prior to 20 6/7 weeks

Exclusion

  • Plan for induction of labor prior to 41 weeks 0 days for medical indication prior to study consideration
  • Plan for cesarean delivery or contraindication to labor
  • Major illness with increased risk of adverse pregnancy outcomes (e.g. pregestational diabetes with or without medication, gestational diabetes on medication, hypertension, cardiac disease, renal insufficiency, autoimmune disorder)
  • Multiple gestation
  • Non-vertex presentation
  • Fetal death
  • Fetus with major/lethal anomaly or aneuploidy (soft markers of aneuploidy, urinary tract dilation, isolated bowel dilation, mild ventriculomegaly, normal variants of vascular system, and isolated ventricular septal defects will not be excluded)
  • a. Soft markers not qualifying as exclusion criteria: echogenic intracardiac focus, choroid plexus cyst, echogenic bowel, increased NT or nuchal fold, isolate short humerus or femur
  • Fetal growth restriction (EFW \<10th percentile or AC \<10th percentile)
  • Preeclampsia or gestational hypertension
  • Known oligohydramnios or polyhydramnios
  • Prior delivery after 20 weeks
  • Placenta/vasa previa
  • Placental abruption (known or suspected) or unexplained vaginal bleeding
  • Previous cesarean section, myomectomy, or classical cesarean
  • Spontaneous labor or suspicion of labor with regular contractions and cervical change, rupture membranes
  • Active genital herpes or HIV positive
  • Inability to consent
  • Any contraindication to a vaginal delivery
  • Delivery anticipated outside of Baystate Medical Center

Key Trial Info

Start Date :

October 31 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2022

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT04035382

Start Date

October 31 2019

End Date

December 31 2022

Last Update

April 13 2022

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Baystate Medical Center

Springfield, Massachusetts, United States, 01199

2

Sidney Kimmel Medical College, Thomas Jefferson University

Philadelphia, Pennsylvania, United States, 19107